G
Gilles Blancho
Researcher at French Institute of Health and Medical Research
Publications - 138
Citations - 5921
Gilles Blancho is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 36, co-authored 98 publications receiving 5104 citations. Previous affiliations of Gilles Blancho include University of Nantes & University of Florence.
Papers
More filters
Journal ArticleDOI
Costimulation blockade with belatacept in renal transplantation.
Flavio Vincenti,Christian P. Larsen,Antoine Durrbach,Thomas Wekerle,Björn Nashan,Gilles Blancho,Philippe Lang,Josep M. Grinyó,Philip F. Halloran,Kim Solez,David Hagerty,Elliott Levy,Wenjiong Zhou,Kannan Natarajan,Bernard Charpentier +14 more
TL;DR: Belatacept, an investigational selective costimulation blocker, did not appear to be inferior to cyclosporine as a means of preventing acute rejection after renal transplantation and may preserve the glomerular filtration rate and reduce the rate of chronic allograft nephropathy.
Journal ArticleDOI
Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens
Jacques Dantal,Maryvonne Hourmant,Diego Cantarovich,Magali Giral,Gilles Blancho,Brigitte Dréno,Jean-Paul Soulillou +6 more
TL;DR: It is found that halving of trough blood cyclosporin concentrations significantly changes graft function or graft survival, and the design of long-term maintenance protocols for transplant recipients based on powerful immunosuppressant combinations should take these potential risks into account.
Journal ArticleDOI
Frequency and Clinical Implications of Development of Donor-Specific and Non–Donor-Specific HLA Antibodies after Kidney Transplantation
Maryvonne Hourmant,Anne Cesbron-Gautier,Paul I. Terasaki,Kazuo Mizutani,Anne Moreau,Aurélie Meurette,Jacques Dantal,Magali Giral,Gilles Blancho,Diego Cantarovich,Georges Karam,Gilles Folléa,Jean-Paul Soulillou,Jean-Denis Bignon +13 more
TL;DR: Screening of HLA antibodies posttransplantation could be a good tool for the follow-up of patients who receive a kidney transplant and allow immunosuppression to be tailored.
Journal ArticleDOI
Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys
Magali Giral-Classe,Maryvonne Hourmant,Diego Cantarovich,Jacques Dantal,Gilles Blancho,Pascal Daguin,Daria Ancelet,Jean-Paul Soulillou +7 more
TL;DR: It is shown that the need for dialysis is not an adequate criterium for DGF in terms of long-term outcome prediction, and a threshold effect in the lesions that ultimately results in long- term functional deficiency is suggested.
Journal ArticleDOI
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials.
Birgit Sawitzki,Paul N. Harden,Petra Reinke,Aurélie Moreau,James A. Hutchinson,David Game,Qizhi Tang,Eva C. Guinan,Manuela Battaglia,William J. Burlingham,Ian S.D. Roberts,Mathias Streitz,Régis Josien,Carsten A. Böger,Cristiano Scottà,James F. Markmann,Joanna Hester,Karsten Juerchott,Cécile Braudeau,Ben James,Ben James,Laura Contreras-Ruiz,Jeroen B. van der Net,Tobias Bergler,Rossana Caldara,William Petchey,Matthias Edinger,Matthias Edinger,Nathalie Dupas,Michael Kapinsky,Ingrid Mutzbauer,Ingrid Mutzbauer,Natalie M Otto,Robert Öllinger,Maria P. Hernandez-Fuentes,Fadi Issa,Norbert Ahrens,Christoph Meyenberg,Sandra Karitzky,Ulrich Kunzendorf,Stuart J. Knechtle,Josep M. Grinyó,Peter J. Morris,Peter J. Morris,Leslie Brent,A. Bushell,Laurence A. Turka,Jeffrey A. Bluestone,Robert I. Lechler,Hans J. Schlitt,M. C. Cuturi,Stephan Schlickeiser,P Friend,Tewfik Miloud,Alexander Scheffold,Antonio Secchi,Kerry Crisalli,Sang-Mo Kang,Rachel Hilton,Bernhard Banas,Gilles Blancho,Hans-Dieter Volk,Giovanna Lombardi,Kathryn J. Wood,Edward K. Geissler,Edward K. Geissler,Edward K. Geissler +66 more
TL;DR: In this paper, the authors evaluated the safety of regulatory CBMPs when combined with reduced immunosuppressive treatment in kidney transplant patients and found that CBMP is achievable and safe in living-donor kidney transplant recipients, and is associated with fewer infectious complications, but similar rejection rates in the first year.